SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma - PubMed (original) (raw)
. 2008 Jan 11;283(2):963-76.
doi: 10.1074/jbc.M707526200. Epub 2007 Oct 19.
Affiliations
- PMID: 17951244
- DOI: 10.1074/jbc.M707526200
Free article
SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma
Gaik Wei Tew et al. J Biol Chem. 2008.
Free article
Abstract
Non-small cell lung carcinoma (NSCLC) is promoted by the increased activities of several small GTPases, including K-Ras4B, Rap1A, Rap1B, RhoC, and Rac1. SmgGDS is an unusual guanine nucleotide exchange factor that activates many of these small GTPases, and thus may promote NSCLC development or progression. We report here that SmgGDS protein levels are elevated in NSCLC tumors, compared with normal lung tissue from the same patients or from individuals without cancer. To characterize SmgGDS functions in NSCLC, we tested the effects of silencing SmgGDS expression by transfecting cultured NSCLC cells with SmgGDS small interfering RNA (siRNA). Cells with silenced SmgGDS expression form fewer colonies in soft agar, do not proliferate in culture due to an arrest in G(1) phase, and exhibit disrupted myosin organization and reduced cell migration. The transcriptional activity of NF-kappaB in NSCLC cells is diminished by transfecting the cells with SmgGDS siRNA, and enhanced by transfecting the cells with a cDNA encoding SmgGDS. Because RhoA is a major substrate for SmgGDS, we investigated whether diminished RhoA expression mimics the effects of diminished SmgGDS expression. Silencing RhoA expression with RhoA siRNA disrupts myosin organization, but only moderately decreases cell proliferation and does not inhibit migration. Our finding that the aggressive NSCLC phenotype is more effectively suppressed by silencing SmgGDS than by silencing RhoA is consistent with the ability of SmgGDS to regulate multiple small GTPases in addition to RhoA. These results demonstrate that SmgGDS promotes the malignant NSCLC phenotype and is an intriguing therapeutic target in NSCLC.
Similar articles
- The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.
Hauser AD, Bergom C, Schuld NJ, Chen X, Lorimer EL, Huang J, Mackinnon AC, Williams CL. Hauser AD, et al. Mol Cancer Res. 2014 Jan;12(1):130-42. doi: 10.1158/1541-7786.MCR-13-0362. Epub 2013 Nov 6. Mol Cancer Res. 2014. PMID: 24197117 Free PMC article. - The Tumor-suppressive Small GTPase DiRas1 Binds the Noncanonical Guanine Nucleotide Exchange Factor SmgGDS and Antagonizes SmgGDS Interactions with Oncogenic Small GTPases.
Bergom C, Hauser AD, Rymaszewski A, Gonyo P, Prokop JW, Jennings BC, Lawton AJ, Frei A, Lorimer EL, Aguilera-Barrantes I, Mackinnon AC, Noon K, Fierke CA, Williams CL. Bergom C, et al. J Biol Chem. 2016 Mar 18;291(12):6534-45. doi: 10.1074/jbc.M115.696831. Epub 2016 Jan 26. J Biol Chem. 2016. PMID: 26814130 Free PMC article. - SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC.
Hamel B, Monaghan-Benson E, Rojas RJ, Temple BR, Marston DJ, Burridge K, Sondek J. Hamel B, et al. J Biol Chem. 2011 Apr 8;286(14):12141-8. doi: 10.1074/jbc.M110.191122. Epub 2011 Jan 17. J Biol Chem. 2011. PMID: 21242305 Free PMC article. - Identification and characterization of the unique guanine nucleotide exchange factor, SmgGDS, in vascular smooth muscle cells.
Thill R, Campbell WB, Williams CL. Thill R, et al. J Cell Biochem. 2008 Aug 1;104(5):1760-70. doi: 10.1002/jcb.21740. J Cell Biochem. 2008. PMID: 18348285 - SmgGDS: An Emerging Master Regulator of Prenylation and Trafficking by Small GTPases in the Ras and Rho Families.
Brandt AC, Koehn OJ, Williams CL. Brandt AC, et al. Front Mol Biosci. 2021 Jun 16;8:685135. doi: 10.3389/fmolb.2021.685135. eCollection 2021. Front Mol Biosci. 2021. PMID: 34222337 Free PMC article. Review.
Cited by
- Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.
Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB. Nithipatikom K, et al. Endocrinology. 2012 Jan;153(1):29-41. doi: 10.1210/en.2011-1144. Epub 2011 Nov 15. Endocrinology. 2012. PMID: 22087025 Free PMC article. - Cell competition and cancer from Drosophila to mammals.
Cong B, Cagan RL. Cong B, et al. Oncogenesis. 2024 Jan 3;13(1):1. doi: 10.1038/s41389-023-00505-y. Oncogenesis. 2024. PMID: 38172609 Free PMC article. Review. - SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.
Schuld NJ, Hauser AD, Gastonguay AJ, Wilson JM, Lorimer EL, Williams CL. Schuld NJ, et al. Cell Cycle. 2014;13(6):941-52. doi: 10.4161/cc.27804. Epub 2014 Jan 16. Cell Cycle. 2014. PMID: 24552806 Free PMC article. - Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells.
Cheng G, Lopez M, Zielonka J, Hauser AD, Joseph J, McAllister D, Rowe JJ, Sugg SL, Williams CL, Kalyanaraman B. Cheng G, et al. Cancer Biol Ther. 2011 Oct 15;12(8):707-17. doi: 10.4161/cbt.12.8.16441. Epub 2011 Oct 15. Cancer Biol Ther. 2011. PMID: 21799303 Free PMC article. - The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif.
Schuld NJ, Vervacke JS, Lorimer EL, Simon NC, Hauser AD, Barbieri JT, Distefano MD, Williams CL. Schuld NJ, et al. J Biol Chem. 2014 Mar 7;289(10):6862-6876. doi: 10.1074/jbc.M113.527192. Epub 2014 Jan 10. J Biol Chem. 2014. PMID: 24415755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials